verified SJR 0,97 · Q1 • database Scopus / SJR & Web of Science & DOAJ indexed

United Kingdom · SAGE Publications Ltd

workspace_premium Q1 — Pulmonary and Respiratory Medicine visibility_off Single blind Peer Review lock_open Open Access · DOAJ

Therapeutic Advances in Respiratory Disease

Therapeutic Advances in Respiratory Disease is a journal indexed in SJR in Pulmonary and Respiratory Medicine and Pharmacology (medical) with an H index of 55. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on respiratory diseases, respiratory disorders, respiratory medicine. It has an SJR impact factor of 0,97 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 0,97.

ISSN: 1753-4658

Publisher: SAGE Publications Ltd

Category: Pulmonary and Respiratory Medicine

Indexation: verifiedScopus / SJR verifiedWeb of Science verifiedDOAJ

open_in_new Portal NPD menu_book Author guidelines

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,97 Q1

H-index 55

Acceptance rate pie_chart

32%

Source Acceptance_Rate

Time to publication hourglass_top

15 weeks

Field Average_time_publication_weeks

Publication cost (APC) payments

1.800 € Open Access

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science DOAJ

SJR Impact

0,97

H-index

Docs (year)

Docs 3y

193

Total refs

3696

Cites 3y

645

Citable 3y

191

Cites/Doc 2y

3.09

Ref/Doc

38.5

Immediate OA

1800 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study

Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone

Diagnostics and epidemiology in ventilator-associated pneumonia

Diagnostic yield and safety of sputum induction with nebulized racemic salbutamol versus hypertonic saline in smear-negative pulmonary tuberculosis

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat¬Æ fixed-dose combination for chronic obstructive pulmonary disease patients in Italy

Current treatment of tracheoesophageal fistula

Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps

Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression

Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis

Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety

Combination therapy for the treatment of pulmonary arterial hypertension

Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease

SHOW MORE ARTICLES

Clinical assessment of the obstructive sleep apnoea/hypopnoea syndrome

A new horizon in the treatment of biofilm-associated tonsillitis

Bronchoscopic staging of lung cancer

Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies

Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance

Are nicotine replacement therapy, varenicline or bupropion options for pregnant mothers to quit smoking? Effects on the respiratory system of the offspring

Antiprotozoal drugs in the treatment of respiratory allergy: a side that should be explored

Antifungal medication is efficient in the treatment of sarcoidosis

An update on the use of indacaterol in patients with COPD

An update on the efficacy of endobronchial valve therapy in the management of hyperinflation in patients with chronic obstructive pulmonary disease

Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis

Advances in the diagnosis of pleural disease in lung cancer

FAQs

Therapeutic Advances in Respiratory Disease has an SJR of 0,97 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 1800 EUR.

The acceptance rate recorded for Therapeutic Advances in Respiratory Disease is 32%.

Therapeutic Advances in Respiratory Disease

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Therapeutic Advances in Respiratory Disease?

What is the APC / publication cost?

What is the acceptance rate?